Rabbit Syndrome
Neurol102:e209275, Huynh,T.U., & Beckley, E.H., 2024
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Reversible Parkinsonism and Ataxia Associated With High-Dose Octreotide
Neurol 70:2345-2346, Espay,A.J., 2008
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
HIV-Related Movement Disorders, Epidemiology, Pathogenesis and Management
CNS Drugs 16:663-668, Cardoso,F., 2002
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
A Survey of Antidepressant Drug Use in Parkinson's Disease
Neurol 49:1168-1170, Richard,I.H.,et al, 1997
Extrapyramidal Side Effects with Low-Dose Risperidone
Can J Psychiatry 42:325-325, Brown, E.S., 1997
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Parkinsonism-Recognition and Differential Diagnosis
BMJ 310:447-452, Quinn,N., 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Disabling Parkinsonism Due to Lithium: A Case Report
J Geriatr Psychiatry Neurol 8:118-119, Holroyd,S. & Smith,D., 1995
Clinical Assessment of Extrapyramidal Signs in Nursing Home Patients Given Antipsychotic Medication
Arch Int Med 154:1113-1117, Avorn,J.,et al, 1994
Reversal of Amphotericin-B-Related Encephalopathy
Neurol 44:1183-1184, Balmaceda,C.M.,et al, 1994
Nigral Dysfunction in Drug-Induced Parkinsonism:An F-dopa PET Study
Neurol 43:552-556, Burn,D.J.&Brooks,D.J., 1993
The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyramidal Movement Disorders
Arch Int Med 153:1469-1475, Ganzini,L.,et al, 1993
Progression After Chronic Manganese Exposure
Neurol 43:1479-1483, Huang,C.C.,et al, 1993
Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism
Neurol 43:836-838, May,E.F.,et al, 1993
Drug-Induced Movement Disorders:An Overview
In Movement Dis in Neurol & Neuropsych, Blackwell Sci Publ, Boston, 2:21., Miller,L.G.&Jankovic,J., 1992
Cyanide-Induced Parkinsonism:Clinical, MRI, and 6-Fluorodopa PET Studies
Neurol 39:142-144, Rosenberg,N.L.,et al, 1989
Diltiazem-Induced Parkinsonism
Am J Med 87:95-96, Dick,R.S.&Barold,S.S., 1989
Induction of Parkinsonism by Intraventricular Bethanechol in a Patient with Alzheimer's Disease
Neurol 39:1265, Fox,J.H.,et al, 1989
Parkinsonism and Amiodarone Therapy
Ann Neurol 25:630-632, Werner,E.G.&Olanow,C.W., 1989
Mild Parkinsonism in Persons Exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
Neurol 39:1483-1487, Tetrud,J.W.,et al, 1989
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Parkinsonism, Tremor, and Depression Induced by Cinnarizine and Flunarizine
BMJ 297:722-723, Capella,D.,et al, 1988
Calcium Channels & Calcium Channel Antagonists
Ann Neurol 21:317-330, Greenberg,D.A., 1987
Classification of Parkinsonism
in Handbook of Parkinson's Disease, Marcel Dekker, Inc, New York, Ch 3, p 61., Koller,W.C., 1987
Parkinsonism, Tardive Dyskinesia, Akathisia, & Depression Induced by Flunarizine
Lancet 1:1303-1304, Chouza,C.,et al, 1986
Metoclopramide-Induced Parkinsonism in Hemodialysis Patients
Arch Int Med 146:2070-2071, Sirota,R.A.,et al, 1986
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
The Clinical Syndrome of Striatal Dopamine Deficiency, Parkinsonism Induced by MPTP
NEJM 312:1418-1421, Burns,R.S.,et al, 1985
Permanent Human Parkinsonism Due to 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP) :Seven Cases
Neurol 35:949-956, Ballard,P.A.,et al, 1985
Chronic Parkinsonism Secondary to Intranasal Administration of a Product of Meperidine-Analogue Synthesis
NEJM 310:325, Wright,J.M.,et al, 1984
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Exacerbation of Parkinsonism by Methyldopa
JAMA 244:2727-2728, Rosenblum,A.M.&Montgomery,E.B., 1980
Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism
Neurol 104:e213365, Yi,M.Y.,et al, 2025
Juvenile-Onset Dopa-Responsive Dystonia-Until It Isnt
Neurol 104:e213436, Paredes,N.C.,et al, 2025
Genetic Causes of Cerebral Small Vessel Diseases, A Parctical Guide for Neurologists
Neurol 100:766-783, Manini,A.,&Pantoni,L., 2023
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
MR Imaging Patterns and Prognosis in Powassan Virus Encephalitis
Neurologist doi.10.1097/NRI.0000000000000533, Finelli,P.F., 2023
Glial Fibrillary Acidic Protein Autoimmunity
Neurol 98:e653-e668, Gravier-Dumonceau, A.,et al, 2022
Reversible Parkinsonism Caused by Lumboperitoneal Shunt Overdrainage
Neurol 99:486-488, Takeuchi, H.,et al, 2022
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
The Phenotypic Continuum of ATP1A3-Related Disorders
Neurol 99:e1511-e1526, Vezyroglou,A., et al, 2022
Rapidly Progressive Thalamic Dementia
Neurol 96:e809-e813, Rizzo, A.C.,et al, 2021
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021